Results 211 to 220 of about 1,825,564 (240)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

A RESPONSE to anti-IL-5 therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: Study protocol. [PDF]

J Allergy Clin Immunol Glob
Bakakos P, Alobid I, Constantinidis J, Hellings P, Pfaar O, Taillé C, Bañas-Conejero D, Kallinikou K, Howarth P, Schleich F.   +9 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study). [PDF]

Eur Respir J
Soendergaard MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, Hilberg O, Hansen S, von Bulow A, Porsbjerg C.   +7 more
europepmc   +1 more source

Human nasal epithelial cells express IL-5Rα but not the co-receptor CSF2RB and do not signal to IL-5. [PDF]

Allergy
Sohail A, Cho L, Hacker J, Bergmark RW, Lee SE, Maxfield A, Roditi RE, Dwyer DF, Buchheit KM, Laidlaw TM.   +9 more
europepmc   +1 more source

[Expression Levels and Clinical Significance of Serum IL-4, IL-5, IL-6, IL-13 and IL-17 in Children With <i>Mycoplasma pneumoniae</i> Infection Accompanied by Airway Hyperresponsiveness]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban
Jin Y, Zhu M, Song L.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

IL-5 and eosinophilia

Current Opinion in Immunology, 2008
While Interleukin-5 (IL-5) is initially identified by its ability to support the growth and differentiation of activated B cells, overexpression of IL-5 significantly increases eosinophil numbers and antibody levels predominantly from an expanded population of B-1 cells in vivo. Conversely, mice lacking a functional gene for IL-5 or IL-5 receptor alpha
Kiyoshi, Takatsu, Hiroshi, Nakajima
openaire   +2 more sources

New frontiers for IL-5

Journal of Allergy and Clinical Immunology, 1997
Part 1 ; Christopher J. Bagley, Angel F.
Bagley, C., Lopez, A., Vadas, M.
openaire   +3 more sources

Interleukin-5 (IL-5)

1995
Abstract The cDNA sequence for human and mouse (GenBank accession numbers X04688 and X06270) predict proteins of 134 and 133 amino acids, respectively. Sequence information is available for both the human and mouse genomic genes (GenBank accession numbers J02971 and XO6271).The coding sequence of the IL-5 gene forms four exons.
openaire   +1 more source